In short
- Boots is close to a new owner. Sycamore Partners is in advanced talks to sell the Boots group to the Weston family’s Wittington Investments for roughly GBP 7bn, or about GBP 6.7bn including debt, according to reports first carried by The Wall Street Journal and The Telegraph.
- The timetable is weeks, not months. Reports published on October 1 said an agreement could be signed in the coming weeks after talks collapsed over the summer and were revived in September.
- It unwinds a one-year holding period. Sycamore only acquired Boots in August 2025, as part of its USD 23.7bn take-private of Walgreens Boots Alliance, then broke the group into separate units.
- The buyer already runs drugstores. Weston family vehicles control Loblaw and Shoppers Drug Mart in Canada, Associated British Foods and Primark in the United Kingdom, and Fortnum & Mason in London.
- A London listing is the casualty. An initial public offering of Boots had been the stated fallback if a sale failed, and a signed deal removes what would have been one of the largest UK retail flotations in a decade.
Boots, the 2,000-store health and beauty chain that has been owned by American capital for almost two decades, is on the verge of returning to a family-controlled holding company. Reports published late on September 30 and through the morning of October 1 said Sycamore Partners is in advanced negotiations to sell the business to the Weston family’s Wittington Investments. The reported figure is approximately GBP 7bn, with The Telegraph and Retail Gazette putting the enterprise value at about GBP 6.7bn including debt. At the October 1 rate of GBP 1 to USD 1.3234, GBP 6.7bn is roughly USD 8.9bn.
Neither Sycamore nor Wittington has publicly confirmed the talks. The outlets reporting the discussions describe them as advanced but unsigned, with a possible agreement in the coming weeks. For a chain that has passed through Kohlberg Kravis Roberts, Stefano Pessina’s Alliance Boots vehicle, Walgreens and now Sycamore, the identity of the next owner matters less than what that owner intends to do with roughly 51,000 employees and a pharmacy network embedded in the British healthcare system.
What the Weston family would actually be buying
The asset on the table is not the sprawling Walgreens Boots Alliance of 2024. It is a carved-out Boots group that Sycamore assembled after the take-private closed. Based on the reporting, that group comprises Boots UK and Ireland, Boots Opticians, the No7 Beauty Company, and pharmacy or retail operations in Thailand, Mexico and Germany.
The scale is substantial by any measure. Boots lists approximately 2,000 stores across the United Kingdom and Ireland, more than 51,000 team members across Boots UK, Boots Ireland, Boots Opticians and No7 Beauty Company, and more than 17 million active Advantage Card members, according to figures the company publishes on its corporate site. Those three numbers explain why the business keeps attracting buyers: a near-universal store footprint, a dispensing licence in most of those stores, and one of the largest first-party customer data sets in British retail.
The No7 brand is the part of the group that behaves least like a retailer. It is a consumer products business with wholesale distribution, international licensing and its own innovation pipeline, and it has repeatedly been floated by analysts as a candidate for separate valuation. Reporting indicates that Anthony Hemmerdinger took on broader responsibilities covering No7 earlier in 2026, which signals the unit is being managed as a distinct profit centre rather than a private label.
The leadership picture going into a sale
Ornella Barra chairs the Boots group, having stepped back from the chief executive role earlier in 2026, according to the reporting. Stefano Pessina, the former executive chairman of Walgreens Boots Alliance and the architect of the original Alliance Boots combination, reinvested in Boots as part of the Sycamore transaction and its subsequent split. Tim Wentworth was chief executive of Walgreens Boots Alliance when the Sycamore deal was agreed.
That continuity matters for a buyer. A family office acquiring a regulated pharmacy business across four jurisdictions has a strong incentive to keep the existing management structure rather than impose its own operators, at least through the first full trading year.
How Sycamore got here in under 14 months
Sycamore Partners completed its acquisition of Walgreens Boots Alliance in August 2025, in a transaction reported at USD 23.7bn including debt. The private equity firm’s stated plan was never to run a single global pharmacy conglomerate. It was to separate the pieces: the US Walgreens retail estate, the US healthcare assets, and the international Boots business, each with its own capital structure and its own exit path.
Selling Boots roughly a year after closing is therefore a sequencing decision rather than a reversal. It is also an unusually fast turn for a sponsor-owned asset of this size, and it reflects a market in which buyers for scaled, cash-generative retail have returned after a thin 2024. Sycamore’s willingness to transact at GBP 6.7bn rather than hold for a larger multiple suggests the firm has concluded that the cost of waiting exceeds the likely uplift.
The pattern is familiar to anyone tracking notable retail M&A deals of the past three years: a sponsor buys a conglomerate at a discount to the sum of its parts, separates the units, and sells the cleanest one first to reset the debt stack on the rest.
Why the international pieces complicate the price
Thailand, Mexico and Germany are small relative to the UK and Ireland business, but they are not free. Each adds a separate regulatory regime, a separate pharmacy ownership rule set and a separate currency exposure. Buyers typically discount those tails or seek indemnities, which is one reason reported valuations have moved within a range rather than settling on a single number.
A pure UK and Ireland Boots, with Opticians and No7 attached, would be a simpler asset to underwrite. The fact that the reported deal keeps the international units inside the perimeter suggests Wittington is buying the group as configured rather than cherry-picking.
What the numbers say about the business being sold
Boots has been trading well relative to the wider UK high street. The most recent full-year figures reported alongside the sale talks show revenue of GBP 7.5bn, up 3.2%, and pre-tax profit of GBP 337m, up 25%. Converted at the October 1 rate, that is roughly USD 9.9bn of revenue and about USD 446m of pre-tax profit.
A 25% increase in pre-tax profit on 3.2% revenue growth is the signature of margin repair rather than demand growth. It is consistent with a business that has closed weaker stores, pushed higher-margin own-brand beauty, and taken cost out of its supply chain. That is exactly the profile that makes a sponsor comfortable selling and a long-term holder comfortable buying.
| Boots group metric | Reported figure | USD equivalent at GBP 1 = USD 1.3234 |
|---|---|---|
| Reported enterprise value in talks | About GBP 6.7bn including debt | About USD 8.9bn |
| Headline valuation cited in reports | About GBP 7bn | About USD 9.3bn |
| Earlier valuation discussed in mid-2026 | About GBP 7.5bn | About USD 9.9bn |
| Latest-year revenue | GBP 7.5bn, up 3.2% | About USD 9.9bn |
| Latest-year pre-tax profit | GBP 337m, up 25% | About USD 446m |
| Stores, United Kingdom and Ireland | About 2,000 | Not applicable |
| Employees across the group | More than 51,000 | Not applicable |
| Active Advantage Card members | More than 17 million | Not applicable |
Set that against the backdrop of a British high street where UK retailers cut 18,000 jobs under rising employment costs, and the Boots numbers look better than the sector average. That is part of the pitch to a buyer: this is not a turnaround, it is a compounding asset with a pharmacy moat.
The multiple implied by the reported price
On the reported GBP 6.7bn enterprise value against GBP 7.5bn of revenue, the implied multiple is roughly 0.9 times sales. Against GBP 337m of pre-tax profit, the headline figure is roughly 20 times, though pre-tax profit is not the metric sponsors or trade buyers price off. Without disclosed earnings before interest, taxes, depreciation and amortisation, any enterprise value to EBITDA calculation would be speculation, and the parties have not published one.
What can be said is that the reported price sits below the GBP 7.5bn discussed in mid-2026 and below the GBP 7.5bn to GBP 8bn range that circulated when a London listing was still the base case. The gap is the negotiating history of the past four months rather than a verdict on the business.
Why the deal stalled in August and restarted in late September
This is the second attempt. Reporting indicates the Weston side reduced its offer over the summer, and Sycamore rejected the lowered bid in August 2026. The trigger was partly competitive: the Australian pharmacy group Sigma Healthcare had been in the process and withdrew, removing the tension that supports a price.
Retail Systems reported that the summer negotiations also stalled on economic uncertainty linked to the conflict between the United States and Iran, which affected financing markets and risk appetite across large leveraged transactions. When conditions settled through September, the parties re-engaged at a level closer to the Weston number than the Sycamore number.
What the Sigma Healthcare withdrawal changed
A single remaining bidder is a structurally different auction. Sellers lose the ability to run a final round, and buyers gain the ability to hold a price. The sequence here, a rival exits in summer, the surviving bidder trims its offer, the seller refuses, and both sides return in autumn at a compromise level, is a textbook outcome of a one-horse process.
It also explains why the reported number landed near GBP 6.7bn rather than the GBP 7.5bn of June. Roughly GBP 800m of value, about USD 1.06bn, moved from seller to buyer between the two reported figures. That is the cost of losing competitive tension.
How a revived process usually gets priced
Revived processes rarely return to the original number. The seller has already demonstrated that it will not walk, and the buyer has already demonstrated that it will. What typically closes the remaining gap is structure rather than headline price: deferred consideration, a larger debt component rolled rather than refinanced, or warranty and indemnity cover that shifts risk off the buyer’s balance sheet.
None of those mechanics has been reported here, which is itself informative. It suggests either that the parties settled on a clean cash-and-debt number, or that the structural detail simply has not leaked yet. The financing disclosure at signing will answer the question.
Who blinked on price
On the public record, Sycamore moved further. The firm rejected a reduced offer in August and is reported to be transacting at a level below both its mid-2026 ask and the listing-case valuation. That is a rational choice if the alternative is holding an asset through a UK consumer slowdown while servicing acquisition debt on the wider Walgreens structure.
Wittington, for its part, is paying a premium to the GBP 4bn it received for Selfridges in 2022, which gives a rough sense of the family’s appetite for UK retail at scale. It is a buyer with permanent capital and no fund life, which is the one bidder profile that can out-wait a sponsor.
How Boots fits the Weston family’s existing retail portfolio
The Weston family is not a financial buyer stepping into an unfamiliar category. Through its Canadian holdings it controls George Weston Limited, Loblaw and Shoppers Drug Mart, the largest drugstore chain in Canada. Through the British arm it controls Associated British Foods, which owns Primark, and it owns Fortnum & Mason outright.
Shoppers Drug Mart is the closest operational analogue to Boots anywhere in the Weston system: a national pharmacy chain with a dominant loyalty programme, a beauty business inside the drugstore footprint, and a front-of-store assortment that behaves like convenience retail. The playbook transfers more cleanly than most cross-border retail acquisitions.
Primark offers a different kind of read. Primark’s move into UK home delivery, anchored by a GBP 90m Sheffield fulfilment site, shows the family is willing to fund digital infrastructure for a store-led brand when the economics justify it. Boots already runs a substantial online business, so the question is investment pace rather than strategic direction.
| Asset | Weston vehicle | Category | Geography | Overlap with Boots |
|---|---|---|---|---|
| Shoppers Drug Mart | Loblaw, via George Weston Limited | Pharmacy and beauty | Canada | High, same format and loyalty model |
| Loblaw | George Weston Limited | Grocery | Canada | Low, adjacent sourcing and private label |
| Primark | Associated British Foods | Value apparel | United Kingdom, Europe, United States | Low, shared high street locations only |
| Fortnum & Mason | Wittington Investments | Luxury food and gifting | United Kingdom | Very low |
| Boots, if the deal signs | Wittington Investments | Pharmacy, beauty, optics | United Kingdom, Ireland, plus three other markets | Not applicable |
The Primark demerger runs in parallel
Associated British Foods has committed to demerging Primark before the end of calendar 2027, a separation that its largest shareholder Wittington Investments has publicly backed while signalling it intends to retain majority ownership of both resulting companies. George Weston is set to lead the retained food business and Eoin Tonge has been named chief executive of Primark.
That means Wittington would be absorbing a GBP 7bn pharmacy acquisition at the same time it is managing a FTSE 100 demerger. The two projects do not conflict operationally, but they compete for governance attention and for the family’s balance sheet capacity over the same 15-month window.
What a signed deal does to the planned London listing
An initial public offering of Boots on the London Stock Exchange had been the publicly discussed alternative if a sale could not be agreed. Reporting through June 2026 described a GBP 7.5bn sale process running alongside a possible flotation, with Sycamore keeping both routes open.
A signed sale closes the IPO route. For the London market, that removes what would have been one of the largest UK retail flotations in a decade at a moment when the exchange has been losing listings rather than winning them. For Boots, it removes the quarterly reporting obligations and the free-float discipline that a listing would have imposed.
Why the IPO was always the fallback
Pharmacy chains are difficult IPO candidates. Revenue is partly set by government reimbursement, store estates carry long lease tails, and the beauty business that drives the growth narrative is the smallest part of the revenue base. A trade or family buyer can underwrite those features privately; public-market investors tend to price them as risks.
The practical consequence is that the listing was leverage, not a plan. Keeping an IPO alive gave Sycamore a credible walk-away position during the summer stand-off, which is precisely what a seller needs when the bidder pool has narrowed to one.
Where competition regulators fit in
On the facts reported so far, this is a change of control rather than a consolidation. Wittington does not own a UK pharmacy chain, so there is no obvious horizontal overlap in dispensing, optics or health and beauty retail in the United Kingdom. Primark and Boots sit on the same high streets but sell different categories.
That does not make a review automatic or impossible. The UK Competition and Markets Authority can call in transactions that meet turnover or share-of-supply tests, and it has been active in grocery and convenience retail. Its handling of the Co-op’s takeover of Southern Co-op, where it flagged 19 overlapping stores and proposed accepting remedies, shows the authority will intervene at a granular local level even in deals that look benign nationally.
What a UK review would actually examine
The likely focus areas, if the CMA looks at all, are local overlaps between Boots pharmacies and any Weston-controlled retail outlets in the same catchments, plus any vertical issues arising from Associated British Foods supplying categories Boots sells. Neither looks material on the public record, but the share-of-supply test is flexible enough that parties rarely assume clearance.
There is also a Canadian dimension. A Weston acquisition of Boots would not change Canadian market structure, since Boots does not operate there, so Competition Bureau involvement looks unlikely. Foreign investment screening in the United Kingdom under the National Security and Investment Act is a separate gate, and pharmacy supply chains have attracted attention in other jurisdictions, though a Canadian family office is not the profile that regime was designed to catch.
What changes for suppliers, landlords and staff
The immediate change is the cost of capital. A permanent-capital family owner typically carries less leverage than a buyout fund and faces no exit clock, which usually translates into longer supplier terms and a steadier store investment programme. That is the optimistic reading, and it is the reading Boots management will present internally.
The less comfortable reading is that any new owner paying GBP 6.7bn will want to see the margin trajectory of the last reported year continue. Sustaining a 25% pre-tax profit increase requires either continued cost reduction or category mix shift, and in a 2,000-store estate the first lever is usually property.
Boots has already run multi-year store rationalisation programmes, so the remaining estate is leaner than it was. Understanding how chains decide which stores to close first is useful context for landlords in secondary locations, because the selection criteria rarely start with sales per square foot alone.
What a change of owner means for the supplier base
Boots buys across three very different supply chains: branded pharmaceuticals and generics for the dispensary, global beauty brands for the front of store, and contract manufacturing for No7 and other own-label lines. Each has a different negotiating dynamic and a different sensitivity to ownership change.
Dispensary supply is the least affected, because volumes are driven by prescriptions rather than by merchandising decisions. Branded beauty suppliers watch ownership changes closely, because a new owner can reallocate shelf space toward own-brand lines where the margin is two to three times higher. Contract manufacturers for own-label typically benefit from exactly that shift.
The signal to watch is the next range review. If own-brand share of the beauty assortment rises materially in the first full year under new ownership, the margin thesis is being executed on the shelf rather than in the property portfolio.
Pharmacy funding is the variable nobody controls
A material share of Boots revenue flows through NHS dispensing arrangements, which are set by government rather than by negotiation with the retailer. That is simultaneously the moat and the risk: it guarantees footfall and limits price competition, and it caps the owner’s ability to reprice when input costs rise.
Any buyer model therefore separates the regulated dispensing business from the discretionary beauty, optics and own-brand lines where pricing power actually sits. The reported interest in No7 as a managed unit is consistent with that split.
Why this deal is a signal for the wider retail M&A market
Two features of this transaction make it a reference point rather than a one-off. The first is the holding period. A sponsor selling a flagship carve-out roughly 14 months after closing indicates that the bid-ask spread in large-cap retail has narrowed enough for sponsors to transact rather than wait.
The second is the buyer type. Permanent-capital vehicles, family offices and strategic holding companies have been the marginal buyer in scaled retail for the past two years, precisely because they can underwrite long lease tails and regulated revenue that public markets discount. A GBP 6.7bn clearing price to a family holding company sets a visible benchmark for the next seller.
The counterfactual matters too. Had Sigma Healthcare stayed in the process, the reported price would almost certainly have been higher, and the read-across would have been stronger. As reported, the deal says more about the depth of the buyer pool at this size than about the direction of retail valuations.
What it implies for other sponsor-owned retail assets
Sponsors holding European retail assets acquired in the 2021 and 2022 vintage are approaching the end of typical hold periods with refinancing decisions in front of them. A completed Boots sale gives those sellers a comparable transaction at scale, which tends to accelerate processes that have been stuck on valuation.
It also narrows the set of plausible buyers. If the clearing bid for a high-quality, cash-generative, 2,000-store estate is a family office rather than another sponsor or a trade buyer, the implication is that leveraged financial buyers are not currently competitive at this size in this category.
What to watch next
The near-term signals are procedural and public. A signed sale and purchase agreement, or a formal statement from either side denying the reports, would be the first. Associated British Foods and Wittington disclosures around the Primark demerger are the second, because they will reveal how the family intends to fund a GBP 7bn acquisition alongside a demerger.
| Trigger | Expected window | Why it matters |
|---|---|---|
| Signed agreement or formal denial | Weeks, per reporting on October 1 | Converts reported talks into a disclosable transaction |
| Financing structure disclosed | At or shortly after signing | Reveals the leverage the estate will carry |
| UK merger notification, if any | Post-signing | Determines whether local store remedies arise |
| Primark demerger progress | Through calendar 2027 | Competes for Wittington balance sheet and governance capacity |
| Boots next full-year results | Next reporting cycle | Tests whether 25% profit growth was repeatable or a reset year |
The broader point for anyone tracking retail ownership is that scaled, cash-generative store estates are trading again, and they are trading to buyers with permanent capital rather than to sponsors with fund lives. Boots at GBP 6.7bn is the largest test of that thesis in UK retail this year. Full corporate detail on the group’s footprint is published on the company’s own Boots in numbers page.
Frequently asked questions
Who is buying Boots?
Reports published on September 30 and October 1, 2026 say the Weston family’s holding company Wittington Investments is in advanced talks to buy the Boots group from Sycamore Partners. The Weston family also controls Associated British Foods and Primark in the United Kingdom, Fortnum & Mason in London, and Loblaw and Shoppers Drug Mart in Canada. Neither party has publicly confirmed the discussions.
How much is the Boots deal worth?
The figures cited in reporting are approximately GBP 7bn as a headline valuation and about GBP 6.7bn including debt. At the October 1, 2026 rate of GBP 1 to USD 1.3234, GBP 6.7bn is roughly USD 8.9bn and GBP 7bn is roughly USD 9.3bn. An earlier stage of the process in mid-2026 was discussed at about GBP 7.5bn.
Why is Sycamore Partners selling Boots after only a year?
Sycamore acquired Boots in August 2025 as part of a USD 23.7bn take-private of Walgreens Boots Alliance, and its plan was to separate the group into units with their own capital structures and exit routes. Selling Boots first is a sequencing decision consistent with that plan rather than a reversal. It also allows the firm to reset debt on the remaining Walgreens assets.
What businesses are included in the Boots group being sold?
Based on the reporting, the perimeter covers Boots UK and Ireland, Boots Opticians, the No7 Beauty Company, and pharmacy or retail operations in Thailand, Mexico and Germany. That makes it a multi-jurisdiction health, beauty and optics group rather than a single-country chain. The United Kingdom and Ireland business is by far the largest part.
How big is Boots?
Boots reports approximately 2,000 stores in the United Kingdom and Ireland, more than 51,000 team members across Boots UK, Boots Ireland, Boots Opticians and No7 Beauty Company, and more than 17 million active Advantage Card members. Its latest reported revenue was GBP 7.5bn, up 3.2%, with pre-tax profit of GBP 337m, up 25%.
Does the Boots IPO still happen if the sale signs?
No. A London listing had been the publicly discussed alternative if a sale could not be agreed, and a signed sale closes that route. The practical effect is that one of the largest potential UK retail flotations of the decade comes off the table at a time when the London market has been losing listings.
Will competition regulators block a Weston acquisition of Boots?
There is no obvious horizontal overlap, because Wittington does not currently own a UK pharmacy chain, and Primark sells different categories from Boots. The UK Competition and Markets Authority can still call in transactions under turnover or share-of-supply tests, and it has intervened at a local-store level in recent retail deals. On the public record a prohibition looks unlikely, though parties rarely assume clearance in advance.
Why did the first attempt at this deal fail in August 2026?
The Weston side reduced its offer after the Australian pharmacy group Sigma Healthcare withdrew from the process, which removed competitive tension, and Sycamore rejected the lowered bid. Reporting also cites economic uncertainty tied to the conflict between the United States and Iran as a factor in the summer stall. Talks resumed in late September at a level closer to the buyer’s number.
What does this mean for Boots shoppers and staff?
Nothing changes at store level on signing, and a permanent-capital family owner typically carries lower leverage than a buyout fund, which usually supports steadier store investment and supplier terms. The counterweight is that a buyer paying GBP 6.7bn will expect the recent margin trajectory to continue, and in a 2,000-store estate property is usually the first lever. No store closure programme has been announced in connection with the reported deal.